←
Nathan Reticker-Flynn426 posts
Nathan Reticker-Flynn avatar

Nathan Reticker-Flynn

@RetickerFlynn

Tumor Immunologist and Engineer @Stanford.

◷ Joined November 2018▧ 16 Photos and videos
Nathan Reticker-Flynn avatar
Nathan Reticker-Flynn@RetickerFlynn·6 May 2022

Tumors spread to lymph nodes before they metastasize to distant tissues, but for over a century scientists have debated whether this matters. It does. Check out our paper online now @CellCellPress @CellPressNews cell.com/cell/fulltext/S0092… 1/15

Kamila Naxerova avatar
⟳ Nathan Reticker-Flynn retweeted
Kamila Naxerova@naxerova·Aug 23

Finishing your PhD or looking for a post-bac research position? We’re recruiting multiple postdocs and research technicians to study somatic evolution! Come do interdisciplinary science in a friendly, collaborative environment at @harvardmed Genetics. naxerova.hms.harvard.edu/con…

Nathan Reticker-Flynn avatar
Nathan Reticker-Flynn@RetickerFlynn·Jan 30

When tumors colonize lymph nodes, they induce a LOT of changes to the immune and stromal populations in the involved LN and beyond, throughout the induction of Metastatic Tolerance. Check out this great study and rich resource describing these changes. Congrats @Max_Haist !

Online Now: Lymph node colonization induces tissue remodeling via immunosuppressive fibroblast-myeloid cell niches supporting metastatic tolerance dlvr.it/TQflcw

Post attachment
AACR avatar
⟳ Nathan Reticker-Flynn retweeted
AACR@AACR·5 Dec 2025

Evolution Under Therapy: Resistance Mechanisms— Andrew J. Aguirre, Nathan E. Reticker-Flynn, Susan M. Rosenberg, and Kathleen Burkhardt addressed this topic in a plenary session at the AACR Special Conference on Cancer Evolution. #AACRevol25 @RetickerFlynn @SusanRosenberg8

Post attachment
Anusha Kalbasi avatar
⟳ Nathan Reticker-Flynn retweeted
Anusha Kalbasi@xrtcell·21 Nov 2025

What if nature already has the optimal cytokine solution for T cell therapy, but we just haven’t found it yet? Check out our paper out today in Immunity on IL-9 as a naturally orthogonal cytokine ideally tuned for T cell therapy authors.elsevier.com/sd/arti… 1/9

Cort Breuer avatar
⟳ Nathan Reticker-Flynn retweeted
Cort Breuer@CortBreuer·10 Nov 2025

Thrilled to see Mario's work on FSP1 out, providing evidence in melanoma alongside lung cancer that there may be alternatives for targeting ferroptosis! Glad we could help with this work including providing our LN metastasis model for in vivo validation

nature@Nature6 Nov 2025

Nature research paper: Lymph node environment drives FSP1 targetability in metastasizing melanoma go.nature.com/4oiPnY2

Nathan Reticker-Flynn avatar
Nathan Reticker-Flynn@RetickerFlynn·21 Sep 2025

Tumors often metastasize to lymph nodes before distant sites, yet evidence suggests that distant mets can originate from unique clones. Is this divergent seeding random? No. Check out our newest @biorxivpreprint to learn how the mechanisms diverge and how to harness them for IO.

I’m excited to share the first major story from my PhD today on the complex role of type 1 interferon in metastasis and immunotherapy! This work was made possible with the support of @RetickerFlynn, Marcos Labrado, and the incredible protein engineer @grayerodriguez

Anusha Kalbasi avatar
⟳ Nathan Reticker-Flynn retweeted
Anusha Kalbasi@xrtcell·13 Aug 2025

Pleasure to share a tremendous body of work from @YangZhao102, who led the next chapter of the powerful orthogonal IL-2 technology from the Garcia Lab (where the innovative spirit is unmatched). Grateful for this ongoing collaboration, stay tuned for more. rdcu.be/eACgC